Our latest articles
Xylocor sees enough to press on with angina gene therapy
A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?
Immuno-oncology goes subcutaneous
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.
Medtech investments hold up despite market turmoil
Medtech venture funding started strongly in 2022, but a slump in the fourth quarter could give rise to concern.
A year to forget for medtech stocks
The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
The world's twelfth VEGF drug will be sold by Takeda
The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.
Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression
39% of the patients assessed carried this biomarker, the conference presentation reveals.
Asco-GI 2023 – zolbetuximab opens up a stomach cancer niche
Clinical data back Claudin18.2 as a target for treating stomach cancer – but biomarker diagnosis is needed.
The first big test for the son of Enhertu
Readout of Tropion-Lung01, testing the most advanced indication for datopotamab, could lead to a first-half US filing.
A year of two halves for US approvals
FDA green lights picked up in the second half, but for the really impressive number look at year-five sales.
Biopharma's stock market winners of 2022 revealed
Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.
